{"organizations": [], "uuid": "25ac941aab4bba86db47eb34e2836ed5430429ed", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cipher-pharmaceuticals-q1-loss-per/brief-cipher-pharmaceuticals-q1-loss-per-share-0-04-from-continuing-operations-idUSASC0A1CD", "country": "US", "domain_rank": 408, "title": "Cipher Pharmaceuticals Q1 Loss Per Share $0.04 From Continuing Operations", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.005, "site_type": "news", "published": "2018-05-10T19:13:00.000+03:00", "replies_count": 0, "uuid": "25ac941aab4bba86db47eb34e2836ed5430429ed"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cipher-pharmaceuticals-q1-loss-per/brief-cipher-pharmaceuticals-q1-loss-per-share-0-04-from-continuing-operations-idUSASC0A1CD", "ord_in_thread": 0, "title": "Cipher Pharmaceuticals Q1 Loss Per Share $0.04 From Continuing Operations", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "cipher pharmaceuticals inc", "sentiment": "negative"}, {"name": "expec", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": " Updated 8 minutes ago BRIEF-Cipher Pharmaceuticals Q1 Loss Per Share $0.04 From Continuing Operations Cipher Pharmaceuticals Inc: * Q1 REVENUE $4.6 MILLION VERSUS $8.1 MILLION\n* EXPECTS TO ADD SIX NEW PRODUCTS FROM ITS EXISTING PIPELINE TO ITS CANADIAN COMMERCIAL PORTFOLIO IN 2018 AND 2019\n* CONTINUES TO PURSUE NEW IN-LICENSING OPPORTUNITIES AND ACQUISITIONS TO FURTHER EXPAND ITS NEAR-TERM PRODUCT PIPELINE\n* EXPECTS ITS GLOBAL LICENSING BUSINESS TO PROVIDE A “SOLID BASE” OF HIGH-MARGIN ROYALTY REVENUE IN 2018 ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-10T19:13:00.000+03:00", "crawled": "2018-05-10T14:25:21.022+03:00", "highlightTitle": ""}